BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

...putting politics ahead of science (see Editor’s Commentary). Oxford BioMedica...
...vaccine supply dealUnder an expanded partnership with Oxford BioMedica plc...
...KB003) AstraZeneca plc Entos Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Sanofi Mayo Clinic Humanigen Inc. Oxford BioMedica plc SARS-CoV-2...
BioCentury | Jun 9, 2020
Product Development

Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic

...overall mortality, especially in light of limited supply (see “More Data Needed” ). Vaccine accessibility Oxford BioMedica plc...
...AZD1222 (formerly ChAdOx1 nCov-19), which the University of Oxford licensed to AstraZeneca plc (LSE:AZN; NYSE:AZN). Oxford BioMedica...
...Deal, Operation Warp Speed Takes First Step” ). Under the new collaboration between VMIC and Oxford BioMedica...
BioCentury | Jun 4, 2020
Management Tracks

Giroir stepping down as COVID-19 testing czar; plus Gilead, Sanofi Ventures, Varian, Sirtex and Oxford BioMedica

...officer of the University of Pennsylvania’s Penn Center for Innovation. Gene and cell therapy company Oxford BioMedica plc...
...BioCentury Staff U.S. Department of Health and Human Services Gilead Sciences Inc. Sanofi Ventures Sanofi Varian Medical Systems Inc. Sirtex Medical Ltd. Oxford BioMedica plc covid-19 Brett...
BioCentury | May 2, 2020
Product Development

Daily Chart: Oxford’s global network of COVID-19 vaccine manufacturing sites

...became Oxford’s latest manufacturing partner this week, joining Cobra Biologics AB, Halix B.V., Merck KGaA, Oxford Biomedica plc...
BioCentury | Apr 30, 2020
Deals

AstraZeneca to make COVID-19 vaccine with roots in Oxford’s CEPI-funded MERS project

...a unit of Danaher Corp. (NYSE:DHR); Cobra Biologics AB; Dutch CDMO Halix B.V.; Merck; and Oxford Biomedica plc...
BioCentury | Feb 11, 2020
Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

...underwritten by Goldman Sachs, Cowen, SVB Leerink and LifeSci Capital. At least two other companies, Oxford BioMedica plc...
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...and Shafique Virani as non-executive director. Heath is deputy chairman and senior independent director at Oxford BioMedica plc...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...$40 million upfront, $830 million in milestones and tiered royalties 2019 Imperial College London ; Oxford Biomedica plc...
...Gene therapy; lentiviral vector Boehringer partnered with the UK Cystic Fibrosis Gene Therapy Consortium and Oxford Biomedica...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...disease,” Yatish Lad told BioCentury. Lad is head of early development at gene therapy company Oxford BioMedica plc...
...the literature, it was quite well known what genes you’d need to deliver.” Yatish Lad, Oxford BioMedica plc...
...and Oxford Biomedica’s gene therapies both encode DDC, the gene responsible for converting L-dopa to dopamine. Oxford BioMedica...
BioCentury | Jun 26, 2019
Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

...to treat pancreatic cancer and acute myelogenous leukemia. Oxford, Santen partner on retinal gene therapies Oxford BioMedica plc...
...Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) VGX-3100 Aimmune Therapeutics Inc. dMed Inovio Pharmaceuticals Inc. Ono Pharmaceutical Co. Ltd. Oxford BioMedica plc Rafael...
Items per page:
1 - 10 of 417
BioCentury | Sep 2, 2020
Product Development

COVID-19 Quick Takes: NAS framework on vaccine allocation prioritizes higher risk groups

...putting politics ahead of science (see Editor’s Commentary). Oxford BioMedica...
...vaccine supply dealUnder an expanded partnership with Oxford BioMedica plc...
...KB003) AstraZeneca plc Entos Pharmaceuticals Inc. Regeneron Pharmaceuticals Inc. Sanofi Mayo Clinic Humanigen Inc. Oxford BioMedica plc SARS-CoV-2...
BioCentury | Jun 9, 2020
Product Development

Lilly’s Junshi-partnered program becomes China’s first COVID-19 mAb in clinic

...overall mortality, especially in light of limited supply (see “More Data Needed” ). Vaccine accessibility Oxford BioMedica plc...
...AZD1222 (formerly ChAdOx1 nCov-19), which the University of Oxford licensed to AstraZeneca plc (LSE:AZN; NYSE:AZN). Oxford BioMedica...
...Deal, Operation Warp Speed Takes First Step” ). Under the new collaboration between VMIC and Oxford BioMedica...
BioCentury | Jun 4, 2020
Management Tracks

Giroir stepping down as COVID-19 testing czar; plus Gilead, Sanofi Ventures, Varian, Sirtex and Oxford BioMedica

...officer of the University of Pennsylvania’s Penn Center for Innovation. Gene and cell therapy company Oxford BioMedica plc...
...BioCentury Staff U.S. Department of Health and Human Services Gilead Sciences Inc. Sanofi Ventures Sanofi Varian Medical Systems Inc. Sirtex Medical Ltd. Oxford BioMedica plc covid-19 Brett...
BioCentury | May 2, 2020
Product Development

Daily Chart: Oxford’s global network of COVID-19 vaccine manufacturing sites

...became Oxford’s latest manufacturing partner this week, joining Cobra Biologics AB, Halix B.V., Merck KGaA, Oxford Biomedica plc...
BioCentury | Apr 30, 2020
Deals

AstraZeneca to make COVID-19 vaccine with roots in Oxford’s CEPI-funded MERS project

...a unit of Danaher Corp. (NYSE:DHR); Cobra Biologics AB; Dutch CDMO Halix B.V.; Merck; and Oxford Biomedica plc...
BioCentury | Feb 11, 2020
Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

...underwritten by Goldman Sachs, Cowen, SVB Leerink and LifeSci Capital. At least two other companies, Oxford BioMedica plc...
BioCentury | Jan 11, 2020
Company News

Management Tracks: Wave CFO departs; plus Polaris, Turning Point, ADC, Relmada, Aravive, Affimed, Impel, Candel and more

...and Shafique Virani as non-executive director. Heath is deputy chairman and senior independent director at Oxford BioMedica plc...
BioCentury | Aug 2, 2019
Product Development

Boehringer plays catch-up in NASH, dives into new modalities across the board

...$40 million upfront, $830 million in milestones and tiered royalties 2019 Imperial College London ; Oxford Biomedica plc...
...Gene therapy; lentiviral vector Boehringer partnered with the UK Cystic Fibrosis Gene Therapy Consortium and Oxford Biomedica...
BioCentury | Jun 27, 2019
Product Development

Gene therapy’s next frontier lies beyond rare, monogenic diseases

...disease,” Yatish Lad told BioCentury. Lad is head of early development at gene therapy company Oxford BioMedica plc...
...the literature, it was quite well known what genes you’d need to deliver.” Yatish Lad, Oxford BioMedica plc...
...and Oxford Biomedica’s gene therapies both encode DDC, the gene responsible for converting L-dopa to dopamine. Oxford BioMedica...
BioCentury | Jun 26, 2019
Company News

June 26 Company Quick Takes: Dupixent approved for nasal polyps; plus Ono/Rafael, Oxford/Santen and more

...to treat pancreatic cancer and acute myelogenous leukemia. Oxford, Santen partner on retinal gene therapies Oxford BioMedica plc...
...Compound #), REGN668 (Compound #), dupilumab (Generic), Dupixent (Informal) VGX-3100 Aimmune Therapeutics Inc. dMed Inovio Pharmaceuticals Inc. Ono Pharmaceutical Co. Ltd. Oxford BioMedica plc Rafael...
Items per page:
1 - 10 of 417